Search research articles

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Recent Highlights in the Discovery and Design of Antibody-Drug Conjugates.

Journal of medicinal chemistry·2026

Same journal

Charting New Territory: Systematic Evaluation of the Drug Potential of <i>N</i>-Trifluoromethyl Amides, Ureas & Carbamates.

Journal of medicinal chemistry·2026

Same journal

Red-Light-Triggered <i>In Vitro</i> and <i>In Vivo</i> Photocatalytic Cancer Therapy with Polypyridyl Os(II) Photocatalysts.

Journal of medicinal chemistry·2026

Same journal

Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity.

Journal of medicinal chemistry·2026

Same journal

HsClpP-Engaging Selective Mitochondrial Pan-PDK Degraders for Cancer Therapy.

Journal of medicinal chemistry·2026

Same journal

Rational Development of Activatable Prodrugs of the GSTP1 Inhibitor NBDHEX: Turn-On NIR Fluorogenic Drug Delivery with Selective Anticancer Activity.

Journal of medicinal chemistry·2026

See all related articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Aug 31, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Selective VPS34 Inhibitors: High Efficiency Design by Profiting from Small Structural Differences.

Pedro M Garcia-Barrantes¹

¹Vertex Pharmaceuticals Inc. 50 Northern Avenue, Boston, Massachusetts 02211, United States.

Journal of Medicinal Chemistry

|August 23, 2022

Summary

This summary is machine-generated.

Researchers developed a selective VPS34 inhibitor for cancer therapy. Compound 5 demonstrates successful kinase selectivity and favorable in vivo pharmacokinetics, offering a promising approach for modulating autophagy.

More Related Videos

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

In Vitro Directed Evolution of a Restriction Endonuclease with More Stringent Specificity

In Vitro Directed Evolution of a Restriction Endonuclease with More Stringent Specificity

Published on: March 25, 2020

Related Experiment Videos

Last Updated: Aug 31, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

In Vitro Directed Evolution of a Restriction Endonuclease with More Stringent Specificity

In Vitro Directed Evolution of a Restriction Endonuclease with More Stringent Specificity

Published on: March 25, 2020

Area of Science:

Oncology
Molecular Biology
Drug Discovery

Background:

VPS34 is a key target for modulating autophagy in cancer treatment.
Developing selective VPS34 inhibitors with appropriate pharmacokinetic (PK) properties presents significant challenges.

Purpose of the Study:

To discover and characterize a selective VPS34 inhibitor.
To evaluate the in vivo pharmacokinetic profile of the identified compound.

Main Methods:

Hit prioritization strategies were employed.
Kinase selectivity was assessed.
In vivo pharmacokinetic studies were conducted.

Main Results:

Compound 5 was identified as a potent and selective VPS34 inhibitor.
The compound demonstrated favorable in vivo pharmacokinetic properties.
Successful kinase selectivity was achieved.

Conclusions:

Compound 5 offers a promising lead for developing novel autophagy-modulating cancer therapeutics.
The discovery highlights effective strategies for hit prioritization and achieving selectivity with good PK profiles.